Neurocrine to Buy Soleno for $2.9 Billion

07:34am, Monday, 06'th Apr 2026
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
Neurocrine's reported biotech buy, Coinbase's new regulatory approval, and more
PepsiCo (PEP) drops sponsorship of a major London music festival after controversy over Kanye West as headliner. Anthropic is being courted by the UK for a London expansion and potential dual listing,
Neurocrine ‌Biosciences will ​acquire ​rare disease drugmaker ⁠Soleno ​Therapeutics ​for $2.9 billion in ​cash, ​the companies said ‌on ⁠Monday.
VYKAT™  XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in  Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Comme
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other gai
SG Americas Securities LLC increased its holdings in Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 171.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Comm
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno"
NEW YORK, April 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 a
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired
New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between M
NEW ORLEANS, April 3, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities
SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno comm
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE